Clinical Development

Rapport Reveals Promising Phase 2a Data for RAP-219 Epilepsy Pill, Plans Phase 3 Trials

3 days ago talkbio0Tagged anti-seizure medication, Clinical Development, drug-resistant epilepsy, Epilepsy, focal onset seizures, RAP-219, Rapport Therapeutics, Seizures

Rapport Therapeutics; RAP-219; epilepsy; seizure reduction; Phase 2a clinical trial; focal onset seizures; Phase 3 trials; anti-seizure medication; drug-resistant epilepsy; clinical development

Editas Medicine Reboots With Cholesterol Gene Therapy (EDIT-401) as Lead Asset

1 week ago talkbio0Tagged Clinical Development, EDIT-401, Editas Medicine, Gene Modification, gene therapy, Hyperlipidemia, in vivo, LDL Cholesterol Lipoproteins, LDLR gene, strategic pivot

Editas Medicine; EDIT-401; gene therapy; hyperlipidaemia; LDL cholesterol; LDLR gene; in vivo gene editing; strategic pivot; clinical development

Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program

1 month ago talkbio0Tagged Chinese biotech, Clinical Development, Inhibitor, Janus kinase, Minghui, Neoplasms, PD-1xVEGF bispecific, pre-IPO ', therapeutic autologous dendritic cells, trials

Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

1 month ago talkbio0Tagged Afimetoran, Autoimmune Diseases, BMS-986322, Clinical Development, Immunology, Investments, Myers, squibb

Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

3 months ago talkbio0Tagged Age-Related Diseases, biotech, biotech merger, Clinical Development, FutureTech II, Longevity, Nasdaq, Public Listing, SPAC

Longevity Biotech; Nasdaq; SPAC deal; public listing; FutureTech II Acquisition Corp.; clinical development; biotech merger; age-related diseases

Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development

3 months ago talkbio0Tagged Clinical Development, daraxonrasib, Neoplasms, Pharma, RAS, RAS cancer, Revolution Medicines, Royalty, secured debt, synthetic royalty

Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding

Cullinan Inks $700M Deal for BCMA Bispecific to Expand Autoimmune T-Cell Engager Portfolio

3 months ago talkbio0Tagged Autoimmune Diseases, biotech partnerships, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, bispecific, CD19xCD3, Clinical Development, CLN-978, Cullinan, Genrix Bio, Multiple Myeloma, T-Cell engager, velinotamig

Cullinan Therapeutics; Genrix Bio; BCMA bispecific; velinotamig; T-cell engager; autoimmune disease; CD19xCD3; CLN-978; multiple myeloma; clinical development; biotech partnerships

Where AI Adds Real Value in Clinical Development: 2025 Insights

4 months ago talkbio0Tagged Aortic Valve Insufficiency, Clinical Development, Clinical Trials, Data Analysis, Drug Discovery, protocol design, Recruitment, Regulatory Compliance

AI in clinical development; clinical trials; drug discovery; protocol design; patient recruitment; data analysis; regulatory compliance

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

9 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Biotechnology, Clinical Development, Cornea, Corneal endothelial dysfunction, Edema, Phase 2 Clinical Trials, Vision

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development

Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments

9 months ago talkbio0Tagged Angitia Biopharmaceuticals, Antibodies, Bispecific, Clinical Development, Musculoskeletal Diseases, Osteogenesis Imperfecta, Osteoporosis, Series, Spinal fusion (procedure)

Angitia Biopharmaceuticals, Series C funding, Musculoskeletal diseases, Osteoporosis, Osteogenesis imperfecta (OI), Spinal fusion, Bispecific antibodies, Clinical development